Canvas Dx

Canvas Dx is the culmination of years of research by leading behavior health experts, conducted in labs at Harvard and Stanford. With FDA-Authorization in 2021 and a rich history of rigorous research, including multiple publications in peer-reviewed medical journals, Canvas Dx stands as a critical milestone in the field of autism.

The technology uses information from various sources to assess a child’s social-communication skills and behavior, enabling the early identification of autism. This includes parent provided videos of the child, along with questionnaires from our physician, all processed using cutting-edge technology.

Cognoa developed and validated Canvas Dx technology using data from a diverse population of children across the U.S. from different social, economic, ethnic, and gender groups. This commitment to inclusivity ensures that our findings are generalizable and equitable.